BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7519672)

  • 1. Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals.
    Mutch D; Underwood J; Geysen M; Rodda S
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):879-90. PubMed ID: 7519672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
    Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.
    Johnson RP; Trocha A; Buchanan TM; Walker BD
    J Exp Med; 1992 Apr; 175(4):961-71. PubMed ID: 1372650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
    Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.
    Hosmalin A; Nara PL; Zweig M; Lerche NW; Cease KB; Gard EA; Markham PD; Putney SD; Daniel MD; Desrosiers RC
    J Immunol; 1991 Mar; 146(5):1667-73. PubMed ID: 1704401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1.
    Bell SJ; Cooper DA; Kemp BE; Doherty RR; Penny R
    Clin Exp Immunol; 1992 Jan; 87(1):37-45. PubMed ID: 1370773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.
    Malhotra U; Holte S; Zhu T; Delpit E; Huntsberry C; Sette A; Shankarappa R; Maenza J; Corey L; McElrath MJ
    J Virol; 2003 Feb; 77(4):2663-74. PubMed ID: 12552005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
    Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE
    Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
    Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
    J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.
    Blazevic V; Ranki A; Krohn KJ
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1335-42. PubMed ID: 8573390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.
    Dorn J; Masciotra S; Yang C; Downing R; Biryahwaho B; Mastro TD; Nkengasong J; Pieniazek D; Rayfield MA; Hu DJ; Lal RB
    J Clin Microbiol; 2000 Feb; 38(2):773-80. PubMed ID: 10655384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.
    Zhan X; Slobod KS; Surman S; Brown SA; Lockey TD; Coleclough C; Doherty PC; Hurwitz JL
    J Virol; 2003 Apr; 77(7):4231-6. PubMed ID: 12634380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission.
    Kuhn L; Coutsoudis A; Moodley D; Trabattoni D; Mngqundaniso N; Shearer GM; Clerici M; Coovadia HM; Stein Z
    AIDS; 2001 Jan; 15(1):1-9. PubMed ID: 11192849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.
    Clerici M; Barassi C; Devito C; Pastori C; Piconi S; Trabattoni D; Longhi R; Hinkula J; Broliden K; Lopalco L
    AIDS; 2002 Sep; 16(13):1731-41. PubMed ID: 12218383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.